Jonathan Landa

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced <i>CDK4</i> -Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Mark A. Dickson, William D. Tap, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2013 · 386 citations · Full text

GPRC5D-Targeted CAR T Cells for Myeloma

Sham Mailankody, Sean M. Devlin, Jonathan Landa et al. · New England Journal of Medicine · 2022 · 367 citations · Full text

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With <i>CDK4</i> Inhibitor Palbociclib

Mark A. Dickson, Gary K. Schwartz, Mary Louise Keohan et al. · JAMA Oncology · 2016 · 310 citations · Full text

Myxofibrosarcoma: prevalence and diagnostic value of the “tail sign” on magnetic resonance imaging

Robert A. Lefkowitz, Jonathan Landa, Sinchun Hwang et al. · Skeletal Radiology · 2013 · 123 citations

Surgical Pathology, Histopathology, Diagnosis +5

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Eric L. Smith, Sham Mailankody, Xiuyan Wang et al. · Cancer Immunology Research · 2019 · 92 citations · Full text